TLR9 and viral infectious disease: On the other hand, other research groups have demonstrated host resistance to bacterial and viral infections via stimulation of MyD88 through TLR2 agonists MALP-2 [protection against S. pneumoniae (36)] or Pam2Cys [Influenza A (37)] or TLR9 agonist CpG [L.